Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord-derived mesenchymal stem cell apoptotic vesicle eye drops
- Development stage
- Unknown
- Lead developer
- Shenzhen Eye Hospital
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cell Therapies
- Administration
- Ophthalmic
01
Overview
Human umbilical cord-derived mesenchymal stem cell apoptotic vesicle eye drops are an experimental biologic therapy developed for the treatment of refractory dry eye disease. The product consists of apoptotic vesicles (ApoVs), which are a subtype of extracellular vesicles released by mesenchymal stem cells (MSCs) during programmed cell death. These vesicles are enriched with bioactive proteins, lipids, and nucleic acids that possess potent immunomodulatory and regenerative properties. When applied topically to the eye, they are intended to suppress ocular surface inflammation, protect and promote the repair of the corneal epithelium, and restore tear film stability. The therapy is currently being evaluated in clinical trials sponsored by Shenzhen Eye Hospital to assess its safety and efficacy in patients who have failed conventional dry eye treatments.
- Other names
- human umbilical cord-derived mesenchymal stem cell apoptotic vesicle eye dropsMSC apoptotic vesicle eye dropshUC-MSC-ApoV eye drops
02
Targets
TAB2SQSTM1 (Sequestosome-1)IRAK1 (Interleukin-1 receptor-associated kinase 1)CASP3 (Caspase-3)
Beyond the preview
Go deeper on human umbilical cord-derived mesenchymal stem cell apoptotic vesicle eye drops.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord-derived mesenchymal stem cell apoptotic vesicle eye drops.